Loading
The phase 3 trials that will decide whether alpha-emitting PSMA drugs become the next step after Pluvicto.
AlphaBreak and AcTION, led by trial NCT06402331, are the phase 3 trials that will decide whether alpha-emitting PSMA drugs become the next step after Pluvicto in PSMA-positive metastatic castration-resistant prostate cancer. AlphaBreak tests FPI-2265, an actinium-225 PSMA-I&T agent from AstraZeneca and Fusion, after lutetium PSMA therapy, while Novartis' AcTION programme tests actinium-225 PSMA-617 in post-lutetium and lutetium-naive settings, and Bayer's PAnTHA phase 1 of 225Ac-PSMA-Trillium reported at ASCO GU 2026; the record lists an enrolment target of 600. OnCo links them to targeted alpha therapy, the actinium-225 PSMA agents record, and to Fusion, AstraZeneca, Novartis and Bayer. Both are recruiting with no results, dry mouth and actinium-225 supply are the constraints, and whether alpha emitters help after lutetium is the question they exist to answer.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Novartis, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Actinium-225 PSMA agents, Targeted alpha therapy, Prostate cancer.
Shares Novartis, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Novartis, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Metastatic castration-resistant prostate cancer, AstraZeneca, Prostate cancer.
Shares Actinium-225 PSMA agents, AstraZeneca, Prostate cancer.
Shares Novartis, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Actinium-225 PSMA agents, Targeted alpha therapy, Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/